Moringa stenopetala (Baker f.) Cudof. and Mentha spicata L. are widely used in the traditional system of medicine for the treatment of diabetes, hypertension, digestive problems and various disorders. The leaves formulation of M. stenopetala and M. spicata herbal tea showed better antidiabetic and antihypertensive effects in rodent models. However, its long-term safety profile has not been investigated yet. Thus, this study investigated the subchronic (90 days) oral toxicity of the leaves formulation of M. stenopetala and M. spicata herbal tea in Wistar albino rats. Four groups of rats (n = 10, with 5/sex/group) were randomly assigned into a control (vehicle) group and three test groups (559.36, 1118.72 and 2237.44 mg/kg, respectively). The three test groups received the herbal tea of M. stenopetala and M. spicata leaves blend daily for 90 days. The control group received distilled water. During the treatment period, clinical signs were observed daily, and food consumption and body weight changes of the rats were measured weekly. At the end of the experiment, macro-pathological, hematological and biochemical parameters were evaluated. Furthermore, histopathology of liver, kidney, heart, stomach and pancreas were examined. Subchronic oral administration of the herbal tea of M. stenopetala and M. spicata leaves blend did not result in death or significant toxicity signs in the treated group rats. Moreover, the herbal tea caused no significant changes on body weight, food intake, organ weight, hematological and biochemical parameters in either sex. However, the serum AST, CK and LDH levels were significantly elevated in rats treated with 2237.44 mg/kg of herbal tea in both sexes. There was no significant alteration in the histology of organs, only minor lesions in the liver, kidney and pancreas were observed. The study results indicate that the herbal tea of M. stenopetala and M. spicata leaves blend is relatively safe/low toxic to rats in subchronic exposure. However, further preclinical (chronic, teratogenic, reproductive and developmental toxicity) studies in animals are required in order to have sufficient safety and toxicity profiles for its use in humans.

Moringa stenopetala and Mentha spicata have long been used to treat diabetes, hypertension, asthma, and other ailments. Herbal tea of M. stenopetala and Mentha spicata leaves formulation showed better antidiabetic and antihypertensive activities. This study investigated the prenatal developmental toxicity potential of the herbal tea of M. stenopetala and M. spicata leaves blend in rats. Wistar pregnant rats were randomly distributed into four groups (n = 8). Group I (control) dams received distilled water. Group II-IV dams were treated with 559.36, 1118.72, and 2237.44 mg/kg of herbal tea of M. stenopetala and Mentha spicata leaves formulations, respectively, during days 5–19 of gestation. Maternal mortality, clinical signs, body weight changes, and food consumption were recorded. On gestation day 20, cesarean sections were performed, and maternal parameters of systemic toxicity (e.g., body weight, serum biochemistry, organ weight, and macro-pathology) as well as reproductive toxicity (e.g., number of corpora lutea, implantations, resorptions (early/late), pre/postimplantation losses, number of fetuses (live/dead), and fetal body weights, length, and their sex ratio) were evaluated. Fetuses were further examined for external, soft tissue, and skeletal alterations. No herbal tea-related maternal deaths or overt toxic symptoms were observed. The measured maternal systemic and reproductive toxicity parameters showed no herbal tea-associated significant alterations at any dosage levels. Moreover, there were no overt toxic effects of the herbal tea on the fetal external, visceral, or skeletal prenatal growth and development. The study findings demonstrated that the herbal tea of M. stenopetala and M. spicata leaves blend could be relatively safe/low toxic to pregnant rats and developing fetuses. The no-observed-adverse-effect level (NOAEL) of herbal tea for maternal toxicity, fetotoxicity, and teratogenicity in rats is estimated to be > 2237.44 mg/kg/day.

Background: Although it appears that an atrial septal defect (ASD) occurs frequently in Ethiopia there are only a few published studies available so far on this matter. This study is therefore aimed to evaluate the prevalence and echocardiographic characteristics of ASDs in children (aged ≤ 15 years) attended a cardiac referral center in Ethiopia. Methods: This retrospective study reviewed the sociodemographic data and the initial echocardiographic findings of the children with ASDs who were diagnosed at the Cardiac Center of Ethiopia (CCE), Addis Ababa, from January 2016 to December 2018. Results: A total of 116 children (56.9% females and 43.1% males) with a mean age of 3.47± 3.72 years (range: 15 days to 15 years) were diagnosed with ASDs. The most prevalent age groups were infancy (50%) and early childhood (29.3%). All the studied cases were diagnosed with ostium secundum ASD while there were no cases with ostium primum, sinus venosus and coronary sinus defects. The most frequent ostium secundum ASD was large size (61.2%) and was more frequent in infants (23.3%) and young children (21.6% of all cases). Conclusion: Ostium secundum ASD is the most prevalent IAS defect and more common among female cases. Large size ostium secundum ASD is more frequent in the studied children and is more prevalent in infants and young children. This survey may provide data for the currently lacking statistics on ASDs at the CCE and might be helpful for the management and follow-up of children with ASDs. Scheduled follow-up and intervention studies are required to evaluate the incidence and patterns of spontaneous and surgical closure of ASD and their outcomes.